Genetic Technologies Limited Announces Research Collaboration with Two Medical Centers

Genetic Technologies (NASDAQ:GENE,ASX:GTG) has announced a research agreement between its subsidiary, Phenogen, Memorial Sloan Kettering Cancer Center, New York and the University of Cambridge.

As quoted in the press release:

This collaborative research study is to be led by Mark Robson, MD, Chief of the Breast Medicine Service at MSK. The study is to assess whether the provision of individual risk information informed by a polygenic risk score (PRS) reduces decisional conflict among BRCA mutation carriers considering preventive surgery.

Executive Chairman of GTG, Dr Paul Kasian said, “the University of Cambridge has one of Europe’s leading academic departments of population health sciences and cancer genetic epidemiology. GTG is proud to be associated with these two prestigious research institutes for this project.

This collaborative study provides two major benefits for GTG:

(i) engagement and collaboration with high profile cancer genetics researchers in the U.S.A.  and Europe who are at the forefront of risk assessment research; and

(ii) the resulting data has the potential to inform the design of future pipeline products for GTG

The specific terms and conditions of the Agreement are confidential but at a high level, GTG will supply novel SNP-based genotyping for a clinical research study, through its CLIA laboratory facility, Phenogen Sciences Inc, on a fee for service basis.”

Click here to read the full press release.